Novel Crystal Form
AssigneeGlaxo Group Limited
InventorMei-yin Lee
Life of this patent
Estimating the term…
Abstract
A novel crystalline form of a compound is disclosed.
Claims20
Crystalline rilapladib characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 1.
Crystalline rilapladib characterized by an X-ray powder diffraction pattern comprising diffraction angles (2 theta) at least at positions of about 6.2, 7.6, 9.1, 11.2, and 14.3 degrees.
Crystalline rilapladib characterized by a Raman spectrum substantially in accordance with FIG. 2.
Crystalline rilapladib characterized by a Raman spectrum comprising peaks at least at positions of about 103, 276, 752, 1155, 1336, 1623, and 3075 cm−1.
Crystalline rilapladib characterized by a melting point of from about 165° C. to about 185° C.
Crystalline rilapladib characterized by an ATR-IR absorption spectrum substantially in accordance with FIG. 7.
Crystalline rilapladib characterized by an ATR-IR absorption spectrum comprising peaks at least at about wavenumbers 2931, 1652, 1621, 1595, 1528, 1494, 1478 1423, 1403, 1327, 1317, 1286, 1237, 1204, 1187, 1166, 1140, 1109, 1066, 1024, 992, 969, 932, 865, 859, 813, 795, 767, 751, 708, and 693.
(canceled)
-21. (canceled)
Dependencies are inferred from the claim text.